These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36216752)

  • 41. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.
    Kan C; Zhang Y; Han F; Xu Q; Ye T; Hou N; Sun X
    Front Endocrinol (Lausanne); 2021; 12():708494. PubMed ID: 34603199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database.
    MacDonald MR; Eurich DT; Majumdar SR; Lewsey JD; Bhagra S; Jhund PS; Petrie MC; McMurray JJ; Petrie JR; McAlister FA
    Diabetes Care; 2010 Jun; 33(6):1213-8. PubMed ID: 20299488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
    Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
    Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
    Luo P; Qiu L; Liu Y; Liu XL; Zheng JL; Xue HY; Liu WH; Liu D; Li J
    Am J Trop Med Hyg; 2020 Jul; 103(1):69-72. PubMed ID: 32446312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus.
    Ma Z; Patel N; Vemparala P; Krishnamurthy M
    Sci Rep; 2022 Apr; 12(1):5553. PubMed ID: 35365744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.
    Geraldine N; Marc A; Carla T; Chantal M; Stefaan B; Welcome W; Frank B
    Diabetes Res Clin Pract; 2012 Aug; 97(2):331-6. PubMed ID: 22386769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin use and mortality and length of stay among hospitalized patients with type 2 diabetes and COVID-19: A multiracial, multiethnic, urban observational study.
    Miao E; Zhang K; Liu J; Lin J; Yoo D; George CJ
    Front Endocrinol (Lausanne); 2022; 13():1002834. PubMed ID: 36440189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use patterns of antidiabetic regimens by patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Gamble JM; Simpson SH
    Can J Diabetes; 2013 Dec; 37(6):394-400. PubMed ID: 24321720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
    Horsdal HT; Mehnert F; Rungby J; Johnsen SP
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):717-25. PubMed ID: 21536457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus.
    Wu CT; Tsai YT; Jung HK; Fu SL; Hsiung CA; Liu HY; Lai JN
    J Clin Pharmacol; 2022 Feb; 62(2):276-284. PubMed ID: 34510471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature.
    Singh AK; Singh R; Saboo B; Misra A
    Diabetes Metab Syndr; 2021; 15(1):159-167. PubMed ID: 33352455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study.
    Yu S; Schwab P; Bian B; Radican L; Tunceli K
    J Manag Care Spec Pharm; 2016 Mar; 22(3):272-80. PubMed ID: 27003557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: a 6-year follow-up study.
    Lin HC; Kachingwe BH; Lin HL; Cheng HW; Uang YS; Wang LH
    Pharmacotherapy; 2014 Jan; 34(1):36-45. PubMed ID: 23864581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metformin plus a low hypoglycemic risk antidiabetic drug vs. metformin monotherapy for untreated type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Hung WT; Chen YJ; Cheng CY; Ovbiagele B; Lee M; Hsu CY
    Diabetes Res Clin Pract; 2022 Jul; 189():109937. PubMed ID: 35662614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
    Ghotbi AA; Køber L; Finer N; James WP; Sharma AM; Caterson I; Coutinho W; Van Gaal LF; Torp-Pedersen C; Andersson C
    Diabetes Care; 2013 Nov; 36(11):3746-53. PubMed ID: 24089540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.